Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-gremlin-1 monoclonal antibody TST003

A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against gremlin-1 (gremlin1; GREM1; Drm), with potential antineoplastic activity. Upon administration, anti-gremlin-1 monoclonal antibody TST003 specifically targets and binds to gremlin-1, thereby neutralizing gremlin-1 expressed on tumor cells and cancer associated fibroblasts (CAFs). This prevents binding to bone morphogenetic proteins (BMP), specifically to BMP2 and 4, and blocks the gremlin-1-mediated inhibition of BMP signaling pathways. This may lead to increased infiltration of CD8 T-cells into the tumor and may inhibit tumor cell growth and proliferation. Gremlin-1, a BMP antagonist and a member of the tumor growth factor (TGF)-beta superfamily, is overexpressed in a variety of cancer cell types. It is involved in cancer cell growth and proliferation, and promotes epithelial to mesenchymal transition (EMT). Overexpression of gremlin-1 is often associated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GREM1 monoclonal antibody TST003
Code name:14E3
TST 003
TST-003
TST003
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search